Bayer AG (FRA:BAYN) has been given an average recommendation of “Hold” by the twenty-four ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is €80.67 ($93.81).
A number of equities research analysts have recently issued reports on BAYN shares. Credit Suisse Group set a $43.00 target price on SEA and gave the company a “buy” rating in a research note on Thursday, July 4th. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays increased their target price on Intuit from $225.00 to $237.00 and gave the company an “equal weight” rating in a research note on Friday, May 24th. Independent Research set a €290.00 ($337.21) target price on adidas and gave the company a “neutral” rating in a research note on Friday, June 28th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $70.00 target price on shares of Total in a research note on Monday, July 15th.
Shares of BAYN stock traded up €0.79 ($0.92) during trading hours on Friday, reaching €59.55 ($69.24). The company had a trading volume of 3,075,454 shares. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98). The company’s fifty day simple moving average is €56.65.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: What is a capital gains distribution?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.